Ultraviolet B Phototherapy Intervention in Patients with Multiple Sclerosis: A Prospective, Randomized Pilot Trial

Robert W. Motl[1], Grace M. Niemiro[2], Michael De Lisio[3], Sarah Sommer[3], Barry J. Riskin[2,4],   Catherine A Best-Popescu[4,5,*]

[1]Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, USA (Robert W. Motl, PhD);

[2]Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA (Grace M. Niemiro, BS, and Sarah Sommer, MPH)

[3]School of Human Kinetics, Brain and Mind Institute, Center for Neuromuscular Disease, and Regenerative Medicine Program, University of Ottawa, Ottawa, ON, Canada (Michael De Lisio, PhD);

[4]University of Illinois College of Medicine, Urbana-Champaign, Urbana, IL, USA (Barry J. Riskin, MD)

[5]Department of Bioengineering, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA (Catherine Alicia Best-Popescu, PhD)

Abstract

Introduction: There is substantial evidence, from well-conducted epidemiological studies, that decreased sun exposure and low vitamin D levels are correlated with an increased risk for multiple sclerosis (MS), and multiple case control studies have implicated the involvement of low vitamin D levels in MS etiology. However, vitamin D supplementation has not been universally successful at raising circulating vitamin D (25-hydroxy vitamin D; 25(OH)D) levels, and has not conclusively reduced MS progression. Thus, interest has turned to studying the therapeutic potential of ultraviolet B radiation (UVB, 280 - 315 nm) in MS disease regulation, because UVB initiates vitamin D synthesis. Additionally, ultraviolet radiation through vitamin-D-independent processes is being considered as an important modifiable modulator of MS pathogenesis.

Objectives: To investigate UVB induced vitamin D production, immunomodulation and MS symptomology following UVB phototherapy in a MS cohort.

Methods: Using a triple blinded, randomized placebo-controlled trial (RCT) study design, twelve individuals 18 years or older with MS were enrolled and assigned (1:1) into individualized UVB dose (10-30kJ/m) phototherapy, or into placebo treatment (fluorescent non-UVB light irradiation), delivered 3 times per week, for 8-weeks. Serum vitamin D (25-hydroxy vitamin D; 25(OH)D) levels, walking performance, strength, cognitive function, mood and circulating progenitor cells (CPCs: $CD34^+CD45^{dim}$), monocyte populations (Intermediate $CD14^+CD16^+$, Classical $CD14^+CD16^-$), and Regulatory T cell ($CD4^+/CD25^+/FoxP3^+$Tregs) count were assessed. The data were analyzed by 2 x 3 mixed factor ANOVA.

Results: A statistically significant condition (UVB phototherapy) by time interaction on vitamin D levels ($F=7.14$, $p<.005$ partial style="">$\eta^2=.42$) was identified. No significant </.005>effects of UVB phototherapy on circulating immunomodulatory cells or MS symptomology were detected.

Conclusion: UVB phototherapy corrects vitamin D deficiency and insufficiency, as defined as total serum 25(OH)D levels

Introduction

Multiple sclerosis (MS) is an incurable debilitating autoimmune disorder. It is the most common nontraumatic chronic degenerative disease of the central nervous system (CNS). The worldwide MS prevalence, approximately 2.4 million people, follows an established geographic gradient that directly correlates with latitude and decreased sunlight intensity.[1] The lowest incidence of MS occurs in equatorial regions, and the highest MS prevalence areas occur in temperate regions with low levels of sunlight exposure including: Canada, Northern parts of the US, Northern Europe, Southeastern Australia and Southern New Zealand. The regional MS prevalence distribution led to the early speculation that reduced sunlight exposure, or the subsequent reduction in vitamin D production, is responsible in part for MS disease incidence and activity.[2-4] Numerous epidemiological and preclinical studies have demonstrated associations between reduced sunlight and the risk of MS development and a worsening of MS severity, with reduced sunlight. [4,5] Likewise, vitamin D insufficiency ((25 hydroxyvitamin D (25(OH)D) values between 40-70 nmol/L) and Vitamin D deficiency (25(OH)D values less than 40 nmol/L) have been associated with an increased risk of MS, and with a worsening of MS manifestations and clinical course. [3,6-10] Conversely, there is evidence that sunlight suppresses MS through induced 25(OH)D production. Independent studies show that high levels of vitamin D, or vitamin D adequacy (25(OH)D values greater than 70 nmol/L), is linked with a reduced risk of developing MS, a reduced number of lesions on MRI and a reduced risk of MS relapse. [10, 11]

Vitamin D is a series of secosteroids obtained primarily through skin exposure to ultraviolet B radiation (UVB, 280-315 nm) from sunlight, and through both animal and vegetable dietary sources. The circulating 25(OH)D form of the hormone represents the principle vitamin D reservoir and is used as an indicator of overall vitamin D status. The primary approach for changing 25(OH)D levels in MS has involved supplementation with standard over-the-counter vitamin D preparations.[12, 13] Existing supplementation studies have not been universally successful in raising 25(OH)D levels or in changing MS outcomes.[12-14] The lack of conclusive findings may be related to the uncertainty regarding an optimal supplementation treatment dose, variations in supplementation compliance, as well as differences in individual absorption and metabolism, laboratory techniques and value reporting, or other unknown factors.[8,10] A more recent and alternative approach for increasing 25(OH)D involves the delivery of ultraviolet B irradiation (UVB) using phototherapy.[15]

Sunlight may suppress MS through a 25(OH)D independent mechanism as well. More recent investigations into the inverse relationship between MS incidence and sunlight exposure led to the discovery that a narrow band of light (300–315 nm) prevents experimental autoimmune encephalomyelitis (EAE), which is the animal model of MS, without a change in 25(OH)D levels. [16, 17] This finding led to human clinical trials designed to examine the possible use of this narrow band UVB light (NB-UVB) as a treatment to stop the conversion or progression of MS, as well as to explore the mechanisms of action of the narrow band light. [17, 18] Patients with relapsing-remitting MS (RRMS) treated with NB-UVB had an attenuated systemic immune response accompanied with elevated serum vitamin D levels.[17] The phototherapy for clinically

isolated syndrome (CIS) trial (PhoCIS trial) found that 12 months of NB-UVB treatment given to CIS patients resulted in a halt or delay in MS conversion in 30% of the NB-UVB study participants as compared to 100% conversion from CIS to MS in the no phototherapy group. CIS is a condition which includes an episode of neurological symptoms caused by CNS inflammation or demyelination that does not fulfil the diagnostic criteria for MS. [18]

The purpose of this study is to evaluate the effects of UVB phototherapy (UVB lamp radiation; 300nm - 311 nm) on serum 25(OH)D levels, immune modulation and clinical benefit. We sought to determine whether UVB phototherapy increases 25(OH)D levels in individuals with MS, and we aimed to investigate whether UVB phototherapy effects circulating immunomodulatory cells or MS symptomology. We chose to investigate immunomodulatory cells, because MS is described broadly as being mediated by activated T-cell and B-cell lymphocytes, and because CNS inflammation is induced through myelin reactive T cells from the peripheral immune system.

Current MS therapies include targeting the destruction, depletion, or suppression of these autoreactive circulating T and B cell lymphocyte populations.[19] Regulatory T cells (Tregs) limit self-reactive cells, and thus have emerged as key immune modulators capable of suppressing pathological autoimmune disease through their maintenance of peripheral immune tolerance. UVB irradiation has been shown to induce the expansion of Treg cells for up to 2 weeks.[20] It is thought that MS results from a disturbance in systemic tolerance mechanisms involving Tregs.[19-24] Tregs prevent the expansion of self-tissue antigens including those directed against myelin determinants. Treg numbers have been shown to be reduced in individuals with MS, and the number of Treg cells are reported to be lower in severe MS forms (Secondary progressive MS (SPMS), Primary progressive MS (PPMS), and Secondary progressive MS (PRMS)), as compared to the mild forms (CIS and RRMS).[21, 23] Thus, boosting Treg cell number, function and migration may prove to be a beneficial MS therapeutic strategy.[19]

Methods

Study Design and Participants

We performed a single center, triple-blind,

randomized placebo-controlled, pilot trial. The study was registered with ClinicalTrials.gov, NCT02365259. The study protocol and ethics were approved by the University of Illinois at Urbana-Champaign (UIUC) Institutional Review Board (IRB). All participants provided written informed consent. Participant screening was undertaken over the telephone by the project coordinator, and participants were not enrolled until after receiving verification of inclusion and exclusion criteria status, and approval for participation by the study neurologist.

Community-residing women and men 18 years of age or older, with relapsing MS were recruited into the study provided that they did not have any of the following exclusion criteria: (a) inability to stand still in a stabilized fashion without risk of falling for up to 6 minutes; (b) medical history of calcium disorder or knowledge of high calcium levels; (c) medical history of hyperparathyroidism; (d) current supplementation with oral vitamin D; (e) allergy to vitamin D; (f) history of cancer of any type including but not limited to skin cancer; (g) obesity defined as body mass index > 30; (h) history of fat malabsorption conditions (i.e., steatorrhea); (i) current use of anti-epileptic medication; (j) current use of glucocorticoids; (k) Fitzpatrick skin types I and VI; and (l) current use of tanning facilities, were recruited into the study. The study subjects were diagnosed with relapsing-remitting MS (RRMS) according to the McDonald criteria. [25]

Randomization and Masking

One randomization event occurred during the study. Study enrollees underwent baseline testing, and were randomized into an intervention condition (UVB phototherapy or Placebo control) by a computer-generated random sequence using standard methods. The final sample completing the study included 12 persons with MS who were evenly distributed between treatment conditions. The study participants, site personnel and clinical neurologist involved in the study were masked to the results of randomization. The University of Illinois created a conflict management plan for monitoring and minimizing bias and undue influence in running the trial and interpreting the data. The study phototherapy technician responsible for administering the intervention treatment was the only person aware of the intervention

assignments.

Procedures

Serum 25(OH)D level, circulating progenitor, monocyte subsets, and Treg numerical status, walking performance, hand-grip strength, cognitive function and mood were assessed at baseline, 4 weeks and again at 8 weeks after beginning the UVB phototherapy or placebo-controlled intervention. The UVB intervention condition consisted of an individualized regimen. Each sub-minimal erythema dose (10-$30 kJ/m^2$) of UVB (Sun Health FS UVB 298-313 nm, 40WT10) phototherapy delivered was based on skin sensitivity, and took into consideration subject Fitzpatrick skin type classification per the 2014 guidelines issued by the American Academy of Dermatology (AAD).[26] The regimen was pilot tested for safety, standardized and manualized for reproducibility. UVB phototherapy was delivered 3 times per week over the 8-week period with a minimum of 24 hours between exposures. The placebo-controlled condition (sham light) was identical in every component as the intervention, except that participants were exposed to non-UVB florescent light (Philips 40WT, alto supreme T12, 4100K). The subjects received the phototherapy or placebo light irradiation to the back, chest, arms and legs through standup medical devices.

The study occurred during the winter in order to avoid confounding the results by varied daytime sunlight exposure. Study participants were also asked not to undertake additional sun or light exposure (i.e., not visit a tanning facility) over the duration of the study, and they were asked to wear protective covering (e.g., hat, long sleeve shirt, and pants) during the hours of 10:00-14:00 daily.

Venous blood was collected from an antecubital vein after an overnight fast at the same time of day for all assessments to quantify 25(OH)D levels. Blood was allowed to clot in serum tubes (BD Vacutainer: Franklin Lakes, NJ) for 60 min at room temperature, then serum was separated by centrifugation at $1300 \times g$ for 15 minutes. Serum was aliquoted and stored at $-80^{\circ}C$ until analysis. 25(OH)D concentrations were quantified in serum by a standard protocol, and based on the manufacturer's instructions (Immunodiagnostic Systems, United Kingdom). All samples were analyzed in triplicate, and 25(OH)D concentrations were expressed as nmol/L.

Circulating progenitor cells (CPCs:

$CD34^+CD45^{dim}$), monocyte populations (Intermediate $CD14^+CD16^-$, Classical $CD14^+CD16^+$), and Tregs ($CD4^+/CD25^+/FoxP3^+$Tregs) were isolated and purified from peripheral blood, stained with FITC- or PE-conjugated antihuman monoclonal antibodies (mAbs), in conjunction with anti-human FoxP3 for the enumeration of T_{reg} cells, and quantified by flow cytometry. PE conjugated monoclonal CD34 (BI-3C5), FITC conjugated monoclonal CD45 (HI30), PE conjugated Monoclonal CD14 (TuK4), and FITC conjugated monoclonal CD16 (3G8) mAbs were used; all antibodies were purchased from Invitrogen (Grand Island, NY). Peripheral blood lymphocytes were stained with BioLegend's True-Nuclear™ Human Treg Flow™ Kit (FOXP3 Alexa Fluor® 488/CD4 PE Cy5/CD25 PE) and were isolated by AutoMACS cell sorter (Miltenyi Biotec). All flow cytometry analysis was performed on a FACSCalibur (BD Biosciences) with BD CellQuest analysis software.

Walking performance was measured using the Timed 25 Foot Walk (T25FW). The protocol involved two trials of walking 25-feet as fast, but safely, as possible. We expressed T25FW performance as ft/sec based on an average of the two trials. This study included a measure of hand-grip strength, wherein participants were asked to squeeze a hand dynamometer (Jamar Hydraulic Hand Dynamometer, Lafayette Instruments, Lafayette, IN) as hard as possible. Participants were given 3 trials per hand with a 1-minute rest between trials, and the highest recorded value was taken as maximal grip strength (kg). Cognitive function was assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery (Langdon DW, 2012) that includes the oral version of the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-II (CVLT-II) and the revised Brief Visuospatial Memory Test (BVMT-R). The SDMT is a timed thinking task that involves associating numbers with symbols; the range of scores is 0-110. The CVLT-II is a test of verbal memory and involves recalling a list of 16 words read aloud by the examiner; the range of scores is 0-90. The BVMT-R is a test of visual memory that involves recalling and manually drawing a series of 6 abstract designs; the range of scores is 0-36. Mood was measured by the 30-item version of the Profile of Mood States (POMS) using a seven-day response set for capturing mood during the past week. We expressed the POMS score by summing the items into Total Mood Disturbance (TMD;

0-80) with lower scores reflected a better overall mood state.

All outcome assessments, data processing and analysis were conducted in a blinded fashion. Participants received remuneration for completing the measurements and for completion of the intervention sessions. Safety and adverse events were assessed at each visit by the study coordinator and were monitored monthly by the UIUC IRB committee.

Statistical Analysis

Data were analyzed using SPSS version 24.0. Results are reported as mean and standard deviation (SD), unless otherwise noted (e.g., percentages, frequencies, medians). We compared initial differences between conditions using independent samples t-tests and chi-square analyses. We compared changes in outcomes over time between conditions based on a mixed-factor, 2-way analysis of variance (ANOVA). Time was a within-subjects factor, whereas condition was a between-subjects factor. We expressed the magnitude of effects as partial eta-squared (η^2) and Cohen's d. All participants who received UVB or placebo were included in the study and safety analysis.

Results

We contacted 40 individuals with relapsing MS about the study, and 35 underwent screening for inclusion. Of these 35 individuals, 18 satisfied inclusion criteria, and 17 were enrolled and scheduled for baseline testing. There were 4 individuals who subsequently withdrew. The remaining 13 individuals underwent baseline testing and were randomized into an intervention condition (UVB phototherapy or placebo control). One person randomized into the phototherapy condition withdrew because of a family event. The final sample completing the study included 12 subjects with relapsing MS who were evenly distributed between treatment conditions (i.e., UVB Intervention, n=6; placebo-controlled condition, n=6); see the trial profile in Figure 1.


Figure 1. Trial Profile
UVB = Ultraviolet B radiation

Table 1. Descriptive characteristics per condition of random assignment.

Characteristic	UVB-Intervention Condition (n=6)	Placebo-Controlled Condition (n=6)	Test Statistic	p-value
Age (yr)	49.2 (14.8)	55.0 (9.6)	t=0.81	.44
Height (cm)	167.1 (6.5)	164.8 (6.8)	t=0.58	.57
Weight (kg)	70.0 (18.3)	76.3 (17.7)	t=0.61	.56
Sex (n/% female)	5/83%	6/100%	χ^2=1.09	.30
Skin type (n/%)				
II	1/17%	0/0%	χ^2=2.14	.34
III	1/17%	3/50%		
IV	4/66%	3/50%		
Assistive Device (n/% none)	6/100%	5/83%	χ^2=1.09	.30

Note. Values are mean score (standard deviation), unless otherwise noted. Skin type

Classifies a person's complexion and his or her tolerance of sunlight. II: white; burns

easily and tans with difficulty. III: cream white; sometimes mild burn and gradually tans. IV:

beige olive; rarely burn and tans easily.

Table 2. Vitamin D Status

	Total Study Subjects			UVB Intervention Condition			Placebo Controlled Condition		
Vitamin D Level	Pre	Mid	Post	Pre	Mid	Post	Pre	Mid	Post
Adequate (>70 nmol/L)	50%	58%	67%	33%	67%	100%	67%	50%	50%
Insufficient (40-70 nmol/L)	25%	25%	17%	50%	33%	0%	0%	17%	17%
Deficient (<40 nmol/L)	25%	17%	17%	17%	0%	0%	33%	33%	33%

The descriptive characteristics of the study participants are provided in Table 1. There were no significant differences between conditions in age, height, weight, or sex, based on independent samples t-tests. All subjects in this study had relapsing MS- that is they were being treated for the occurrence of new symptoms or the worsening of old symptoms. All subjects were on disease modifying therapy. These included glatiramir acetate (Copaxone), interferon beta-1b (Betaseron, Extavia), natalizumab (Tysabri), and fingolimod (Gilenya).

The groups did not differ in skin type nor use of an assistive device for ambulation based on chi-square tests. Pre-study blood draws revealed that 25% of our study subjects were vitamin D deficient, 25% were vitamin D insufficient, and 50% had adequate vitamin D values. Vitamin D deficiency, insufficiency and adequate vitamin D was defined as 25(OH)D values less than 40 nmol/L, 25(OH)D values falling between 40-70 nmol/L and 25(OH)D values greater than 70nmol/L, respectively. At the completion of the study, 100% of the UVB intervention study subjects had adequate vitamin D levels as compared to only 50% of the placebo condition subjects. (see Table 2).

The mixed-factor ANOVA identified a statistically significant condition by time interaction on serum vitamin D levels (F=7.14, p<.005, partial η^2=.42). The UVB intervention condition had an increase in serum vitamin D levels over time, whereas there was no change for the placebo-controlled or sham condition; see Figure 2. The effect size for the change from pre- to mid-testing with the intervention condition was moderate in magnitude (d=0.64), and was large in magnitude (d=1.05) from pre- to post-testing. The condition by time interaction accounted for 42% of the variance in serum 25(OH)D levels.

The descriptive and inferential statistics for the primary and secondary outcomes are provided in Tables 2, 3 and 4, respectively. The mixed-factor ANOVAs for secondary outcomes did not identify statistically significant condition by time interactions on any variable. There was a significant time main effect for revised Brief Visuospatial Memory Test (BVMT-R) scores (F=7.52, p<.005, partial η^2=.43). This time main effect indicates an improvement in BVMT-R scores over time for both treatment conditions (i.e., no treatment effect) and likely reflects a practice effect following the tests repeated administration. CPC, classical monocyte, intermediate monocyte, and Treg numerical status were not found to be correlated with treatment or 25(OH)D level as shown in Table 4 and 5.

Individual longitudinal changes in classical monocyte and Treg numerical status profiles appear different between the UVB treated subjects versus the placebo control group. For subjects 1, 3 and 6 a profile of increased intermediate monocyte, classical monocyte and Treg numerical status following UVB intervention occurred. The differences however, are not statistically significant, and the changes are not uniform across all UVB - treated subjects see Figures 3 and 4.

Discussion

Although this study was unable to show significant UVB-induced MS immunoregulation or neurological improvement over the duration of the study, we do report some compelling observations. The UVB phototherapy condition, unlike the placebo-controlled condition, resulted in a statistically significant increase in serum 25(OH)D levels over the course of the 8-week trial. And while the changes in CPC, classical and intermediate monocyte and Treg cell counts following UVB intervention were not significantly different from those observed in the placebo control group, individual Treg cell profile changes following UVB light treatment, including a marked increase in Treg counts in 4/6 UVB treated individuals versus 1/6 of the placebo treated subjects was noted. This may reflect subject response variability and warrants further investigation. The trend towards an increase in Tregs in this population following UVB treatment represents an exploitable therapeutic potential given that Tregs play a critical role in the active suppression of autoimmunity. MS patients have been found to have lower circulating Treg cell numbers compared to healthy controls, [21-23] and Treg numeric and functional deficiencies have been shown to play a pathogenic role in inflammatory demyelinating CNS disorders. [21, 24]

The observed variations in classical monocyte levels relative to alterations in intermediate monocyte levels may also indicate differences in disease duration, activity, or recovery. Classical monocytes are thought to primarily play a phagocytic role, whilst intermediate monocytes are thought to be associated with an

Figure 2. Time by condition interaction of serum vitamin D levels. Values are mean scores (standard deviation). Intervention Condition referes to the UVB phototherapy, and Placebo-Controlled Condition refers to the florescent light condition. The increase in mean vitamin D concentration from Pre, Mid to Post UVB intervention was stastistically different from the vitamin d values observed in the Placebo contolled condition over the duration of the study from Pre, to mid to post intervention; $p < 0.05$.

Table 3. Descriptive statistics for outcome variables

Outcomes	Variable	UVB Intervention Condition (n=6)			Placebo-Controlled Condition (n=6)		
		Pre	Mid	Post	Pre	Mid	Post
Primary	Vitamin D (nmol/L)	71.7 (37.9)	100.4 (51.6)	124.7 (63.1)	76.5 (41.1)	62.5 (26.8)	70.1 (34.7)
Secondary	T25FW (ft/sec)	5.2 (1.3)	5.3 (1.3)	5.5 (1.3)	4.6 (2.5)	5.4 (2.6)	5.0 (2.6)
	Strength (kg)	33.8 (14.7)	33.5 (11.3)	32.3 (9.8)	29.2 (6.2)	28.0 (8.6)	25.8 (6.5)
	SDMT (0-110)	55.0 (22.1)	59.0 (23.7)	54.0 (13.9)	54.5 (14.1)	57.7 (13.5)	57.7 (12.7)
	CVLT (0-90)	60.3 (7.6)	55.2 (10.9)	60.0 (4.7)	54.3 (9.8)	57.3 (8.8)	58.3 (14.1)
	BVMT-R (0-36)	21.9 (7.4)	25.7 (4.5)	29.2 (4.7)	19.2 (7.9)	19.3 (6.5)	23.8 (7.6)
	TMD (0-80)	36.5 (12.2)	30.0 (15.1)	32.0 (14.5)	32.3 (6.9)	25.0 (10.7)	26.7 (12.7)

Note. Values are mean score (standard deviation); T25FW = Timed 25-Foot Walk; SDMT = Symbol Digit Modalities Test;

CVLT = California Verbal Learning Test; BVMT-R = revised Brief Visuospatial Memory Test; TMD = Total Mood Disturbance.

Table 4. F-values for main effects and interaction from 2-way, mixed factor ANOVAs

Outcomes	Variable	Time		Condition		Time by Condition	
		F-value	p-value	F-value	p-value	F-value	p-value
Primary	Vitamin D	4.32	<.05	1.52	.25	7.14	<.005
Secondary	T25FW	2.57	.10	0.13	.73	0.21	.81
	Strength	2.55	.10	0.98	.35	0.35	.71
	SDMT	1.49	.26	.01	.95	0.78	.47
	CVLT	0.73	.50	.14	.71	1.39	.27
	BVMT-R	7.52	<.005	2.05	.18	0.72	.50
	TMD	2.39	.12	0.65	.44	0.02	.98

Note. T25FW = Timed 25-Foot Walk; SDMT = Symbol Digit Modalities Test; CVLT = California Verbal Learning Test; BVMT-R = revised Brief Visuospatial Memory Test; TMD = Total Mood Disturbance

Table 5. Descriptive statistics for exploratory immune variables

	UVB Intervention Condition (n=6)		Placebo-Controlled Condition (n=6)	
Variable	Pre	Post	Pre	Post
Circulating progenitor cells (CD34+/CD45dim)	0.17 (0.13)	0.17 (0.12)	0.11 (0.05)	0.28 (0.34)
Intermediate Inflammatory monocytes (CD14+/CD16+)	1.07 (0.63)	1.58 (0.68)	1.83 (1.66)	1.83 (1.73)
Classical Phagocytic monocytes (CD14+/CD16-)	2.98 (1.41)	5.66 (3.46)	4.02 (3.04)	4.05 (4.28)
Regulatory T cells -Tregs (CD4+/CD25+/FoxP3+)	5.54 (3.74)	8.52 (4.89)	9.79 (6.15)	9.73 (4.84)

Note. Values are mean score (standard deviation). There are no significant interactions or main effects for the immune variables based on the 2-way ANOVAs.

Figure 3. Individual subject changes in Circulating Progenitor Cells (CPCs, CD34+/CD45dim), Intermediate monocytes (Inflamatory, CD14+/CD16+), Classical monocytes (Phagocytic CD14+/CD16-) and Regulatory T cells (Tregs, , CD14+/cd25+/FoxP3+). Filled black circles are individual Pre-intervention values and the white filled circles are the corresponding Post-intervention values for the 12 study subjects.

Figure 4. Individual longitudinal immune cell changes in the NB-UVB treated group (study subjects 1-6), versus the placebo control group (study subjects 7-12). Grey bars are Circulating Progenitor Cells, CPCs. Black bars are Intermediate Monocytes. White bars are Classical Monocytes. Black and white patterned bars are Regulatory T cells (Tregs).

inflammatory response. An increase in intermediate monocytes could be a differentiating factor between acute and chronic inflammation.[27] It is unclear whether the observed increase in Treg and classical phagocytic monocyte number in a subset of the individuals is a cause or consequence of the disease status, or whether it is related to disease duration or medication differences among the study subjects. Subjects 1, 3 and 6 share a common increase in intermediate and classical monocyte, and Treg numerical status following UVB treatment which is distinct from the other study subjects. There were no UVB phototherapy associated clinical benefits. Cautious interpretation of these results is warranted because the patients were on different immunosuppressive therapies and duration of disease was not adjusted for.

These results complement and extend those reported in a previous study of UVB treatment in persons with MS. [27] Our study design is different from the previous study in that we included a placebo-controlled sham device, as well as treatment- and data-blinded assessors. Collectively, the UVB phototherapy trials show that vitamin D deficiency can be corrected within 8 weeks. A longer study duration is likely to be necessary for improved clinical outcomes to become apparent.

The limitations of the current pilot RCT include the small sample size, the short time course of the study, and the fact that the participants in our study were not all vitamin D deficient at baseline. Additionally, we did not consider disease duration or concurrent therapeutic interventions (medication) in our analysis. These factors did not preclude the demonstration of an intervention effect on serum vitamin D, but undermined our capacity to confidently interpret the UVB-induced changes in CPC, intermediate and classical monocyte, and Treg cell populations, and likely limited our ability to detect differences in secondary clinical end-points. Clinical benefits of UVB phototherapy may be more pronounced in patients with MS that have had a history of chronic vitamin D deficiency. This is important considering the evidence for vitamin D insufficiency and deficiency in MS, [6] combined with the association between serum vitamin D deficiency and both the increased risk of MS and worsening clinical course and MS symptomology, as reflected by radiologic and clinical outcomes over time. [6,9,11, 28, 31, 32]

Our observations have potential therapeutic implications, as the observed immunopathological heterogeneity in MS is likely to be both patient- and context-dependent, and may reflect either different host genetic factors that define different

immune-mediated inflammatory responses, and the subsequent susceptibility to neuronal injury, or distinct triggers, respectively. [29] We expect that the degree of disease chronicity, concomitant illnesses, therapeutics, and individual-specific disease modifying factors, such as: weight; overall health; and prior immunogenic exposures, effect circulating immune cell profiles as well as overall clinical outcome. Variable responses of MS patients to UVB immunomodulatory therapies may also relate, in part, to differences in repair processes or the underlying effector mechanisms mediating disease. These observations have potentially significant implications for individualized MS therapeutic approaches.

Given the report that the prevalence of MS in the US has been on a steady rise over the past 5 decades [30], and because there is currently no curative FDA-approved therapy for MS, novel clinical strategies for the management of MS are needed. In a subset of MS patients, UVB phototherapy may shorten the duration of acute MS exacerbations, decrease relapse frequency and provide symptomatic relief by providing neuroprotection mediated through a decreased autoimmune responsivity mechanism. UVB phototherapy, as a Treg augmentation therapy, may confer immune directed neuroprotective prophylaxis, and may provide therapeutic benefit in MS.

The results presented in this study support the need for larger UVB phototherapy trials of longer duration to further investigate the Treg inductive capability of UVB radiation. In the future, we hope to evaluate UVB –induced immune profile changes, and their relative impact on MS disease course and relapse rate, in relation to vitamin D status. The individual longitudinal changes in the monocyte and Treg numerical status following UVB phototherapy shown here, highlight the necessity of individualized MS therapeutics, and the need for sophisticated computational strategies to aid in complex multivariable patient data analysis. Interventional studies designed to determine whether UVB phototherapy results in immunomodulation and subsequent amelioration of MS disease activity are justified.

We do not advocate chronic excessive sunlight exposure as a MS therapy, because of the associated increased risk of nonmelanoma skin cancer. However, we do support the recommendation for sensible sun exposure, as defined as 5-10 minutes of exposure of the arms, hands, legs and face 2 to 3 times per week, and increased dietary and supplementation of vitamin D intake to help ensure vitamin D sufficiency. This is particularly important in the context of the growing concern about vitamin D deficiency being an unrecognized epidemic among both children and adults in the US. [7]

Conclusion

The results of this pilot trial indicate that UVB phototherapy represents a novel, safe, inexpensive and effective, nonpharmacological approach to increasing vitamin D levels in MS. UVB phototherapy corrects vitamin D deficiency. At the completion of the study, 100% of the UVB treated condition subjects had adequate vitamin D levels as compared to only 50% of the subjects in the placebo controlled condition (see Table 2). Vitamin D's pleiotropic effects on health and role in the immune response suggest that UVB phototherapy may be a successful component in combatting MS. Using UVB phototherapy, as an add-on therapy in this still incurable disorder, may offer a therapeutic approach to control autoimmune inflammation and MS relapse and progression. Based on our findings, and in the context of a growing literature that supports the hypothesis that UVB induces neuroprotection in MS through immunomodulation, larger and longer duration UVB phototherapy studies in MS that consider the multifactorial intrinsic and extrinsic disease modifying factors are warranted. Given that MS is a remarkably heterogeneous condition, future studies should attempt to identify the specific subpopulation of patients most likely to benefit from UVB phototherapy. UVB phototherapy may need to be initiated in early stage MS to confer protection against, or resilience towards, the autoimmune response responsible for CNS injury in MS. This study, like the previous NB-UVB MS clinical trials, provides encouragement to other investigators to conduct larger scale UVB phototherapy studies designed specifically to investigate the potential MS disease modifying effects of UVB phototherapy.

Declaration of Interests

Thus, the University of Illinois created a conflict management plan for minimizing bias and undue influence in the running of the trial and data interpretation by triple blinding the study, and by restricting control of the study and access to the data to the University of Illinois primary investigator. The funding source aims to develop propriety phototherapy devices. The company did not play *any* (italics was added for emphasis) role in the study design, the writing of the manuscript, or in the decision to submit the manuscript for publication.

Conflicts of Interest

Author Contributions

CBP and RM wrote the paper. BJR, BP, GN, MDL, SS and RM conducted the research. CBP and RM conducted the data analysis.

Funding

Acknowledgements

References

1. Simpson S, Blizzard L, Otahal P. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. *J Neurol Neurosurg Psychiatry.* 2011; 82: 1132-1141.

2. Summerday NM, Brown SJ, Allington DR, and Rivey MP. Vitamin D and Multiple Sclerosis Review of a Possible Association. *Journal of pharmacy practice*. 2012; 25 (1):75-84.

3. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis. *JAMA*. 2006; 296(23): 2832–2838.

4. Beretich BD, and Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. *Mult Scler.* 2009; 15:891-898.

5. Lucas RM, Ponsonby AL, and Dear K. Sun exposure and vitamin D are independent risk factors for CNS demyelination *Neurology* 2011; 76: 540-548.

6. Shahbeigi S, Pakdaman H, Fereshtehnejad S-M, Nikravesh E, Mirabi N, Jalilzadeh G. Vitamin D_3 Concentration Correlates with the Severity of Multiple Sclerosis. *International Journal of Preventive Medicine*. 2013; 4(5): 585-591.

7. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease, *The American Journal of Clinical Nutrition*. 2004; 80(6): 1678S–1688S.

8. Mowry EM. Vitamin D: Evidence for its role as a prognostic factor in multiple sclerosis. J Neurol Sci. 2011; 311:19-22.

9. Pierrot-Deseilligny C, Rivaud-Pechoux S, de Paz Clerson PR, Souberbielle JC. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation, *Ther Adv Neurol Disord*. 2012; 5 (4):187-98.

10. Manousaki D and JB Richards, Vitamin D deficiency is an etiological factor for MS-Yes *Multiple Sclerosis Journal*. 2019; 25(5): 637-638.

11. Ascherio A, Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurol.* 2014; 71 (3):306–314

12. James E, Dobson R, Kuhle J, et al. The effect of vitamin D-related interventions on multiple sclerosis relapses: A meta-analysis. *Multi Scler.* 2013; 19: 1571-1579.

13. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomized controlled trial. *Mult Scler.* 2012; 18: 1144-1151.

14. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials

examining the clinical efficacy of vitamin D in multiple sclerosis. *Neuroepidemiology*. 2013; 40: 147-153.

15. Ala-Houhala MJ, Vahavihu K, Hasan T et al. Comparison of narrowband ultraviolet B exposure and oral vitamin D substitution on serum 25-hydroxyvitamin D concentration. *Br J Dermatol*. 2012; 167:160–4.

16. *Wang Y, Marling SJ, Beaver EF*, et al. *UV light selectively inhibits spinal cord inflammation* and *demyelination* in *experimental autoimmune encephalomyelitis. Arch Biochem Biophys 2015*; *567*: *75-82*.

17. Breuer JN, Schwab T, Schneider-Hohendorf M, et al. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. *Ann Neurol*. 2014; 75: 739-758.

18. Hart PH, Lucas RM, Booth DR, et al. Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules. *Frontiers in Immunology*. 2017; 8: 3.

19. Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. *Journal of neuroinflammation. 2017*; 14:17.

20. Yamazaki S, Nishioka A, Kasuya S, et al. Homeostasis of Thymus-Derived Foxp3+ Regulatory T Cells Is Controlled by Ultraviolet B Exposure in the Skin. *J Immunol* 2014; 193(11): 5488–97.

21. Kouchaki E, Salehi M, Reza M, Nikoueinejad H, Akbari H. Numerical status of CD4+CD25+FoxP3+ and CD8+CD28- regulatory T cells in multiple sclerosis *Iran J Basic Med Sci* 2014; 17: 250-255.

22. Venken K, Hellings N, Thewissen M, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. *Immunology*. 2008; 123 (1):79–89.

23. Haas J, Hug A, Viehöver A, et al. Reduced suppressive effect of CD4[+]CD25[high] regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. *Eur. J. Immunol.,* 2005; 35: 3343-3352.

24. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4[+]CD25[+] regulatory T cells in patients with multiple sclerosis. *J. Exp. Med* 2004; 199: 971-979.

25. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for Multiple Sclerosis: 2005 revisions to the McDonald Criteria". *Ann Neurol* 2005; 58: 840-846

26. Sidbury R, David DM, Cohen DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014; 71: 327-349.

27. Mukherjee R, Barman PK, Thatoi PK, et al. Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous. *Sci Reports* 2015; 5:13866.

28. Brola W, Sobolewski P, Szczuchniak W, et al. Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. *EJCN European Journal of Clinical Nutrition* 2016; 70, 995–999.

29. Metz I, Weigand SD, Popescu BFG, et al. Pathologic Heterogeneity Persists in Early Active Multiple Sclerosis Lesions. *Annals of neurology*. 2014; 75(5): 728-738.

30. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States *Neurology* Mar 2019, 92 (10) e1029-e1040.

31. Hartl C, Obermeier V, Gerdes LA, Brugel M, Kries RV, Kumpfel T. Seasonal variations in vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients. J Neurol Sci.2017; 375: 160-164.

32. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. *Multiple Sclerosis Journal*. 2008; *14*(9): 1220–1224.